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Abstract

NIH-PA Author Manuscript

Human onchocerciasis is a neglected tropical disease caused by Onchocerca volvulus and an
important cause of blindness and chronic disability in the developing world. Although mass drug
administration of ivermectin has had a profound effect on control of the disease, additional tools
are critically needed including the need for a vaccine against onchocerciasis. The objectives of the
present study were to: (i) select antigens with known vaccine pedigrees as components of a
vaccine; (ii) produce the selected vaccine antigens under controlled conditions, using two
expression systems and in one laboratory and (iii) evaluate their vaccine efficacy using a single
immunization protocol in mice. In addition, we tested the hypothesis that joining protective
antigens as a fusion protein or in combination, into a multivalent vaccine, would improve the
ability of the vaccine to induce protective immunity. Out of eight vaccine candidates tested in this
study, Ov-103, Ov-RAL-2 and Ov-CPI-2M were shown to reproducibly induce protective
immunity when administered individually, as fusion proteins or in combination. Although there
was no increase in the level of protective immunity induced by combining the antigens into one
vaccine, these antigens remain strong candidates for inclusion in a vaccine to control
onchocerciasis in humans.
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1. Introduction
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Human onchocerciasis is a neglected tropical disease caused by Onchocerca volvulus and an
important cause of blindness, skin disease and chronic disability in the developing world.
Through mass drug administration of ivermectin, onchocerciasis has been recognized as a
potential candidate for control of morbidity (blindness and skin pathology) and for global
elimination by focusing on interruption of transmission (http://www.emro.who.int/
neglected-tropical-diseases/ntd-infocus/ntd-roadmap.html, 2014). In some foci of the
Americas, Mali, Senegal and Nigeria (Kaduna), there has been encouraging evidence that
the elimination of onchocerciasis may be possible with mass drug administration of
ivermectin, when high levels of therapeutic and geographic coverage over many years have
been achieved (Diawara et al., 2009). However, numerous and formidable technical and
logistical obstacles must still be overcome before the ambitious goal of elimination can be
attained in Africa. These include: (i) the practical complication of treating people for 14 - 35
years compounds the difficulty of implementing this plan (Winnen et al., 2002; Boatin and
Richards, 2006); (ii) experimental studies indicate that susceptibility to reinfection may
increase after treatment, further complicating the disruption of the transmission cycle (Duke
and Moore, 1968; Abraham et al., 2002; Njongmeta et al., 2004); (iii) recent reports
demonstrate that O. volvulus in some communities in Africa may have developed resistance
to ivermectin (Huang and Prichard, 1999; Kohler, 2001; Awadzi et al., 2004a, b; Ardelli et
al., 2005; Bourguinat et al., 2005, 2007; Eng and Prichard, 2005; Osei-Atweneboana et al.,
2007); and finally (iv) use of mass drug administration is already compromised in large
areas of central Africa where loiasis is co-endemic. Ivermectin cannot be used for the
treatment of individuals with high Loa loa microfilaremia due to the risk of developing
severe adverse reactions including an encephalopathy (Gardon et al., 1997). Therefore,
additional tools are critically needed and include the need for a vaccine against
onchocerciasis to complement the present control measures and thus potentially eliminate
this infection from humans.
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Protective immunity against O. volvulus larvae has been demonstrated in cattle (Tchakoute
et al., 2006), mice (Lange et al., 1993) and immuno-epidemiological studies strongly support
the hypothesis that protective immunity against onchocerciasis exists in humans
(MacDonald et al., 2002), thereby proving the conceptual underpinnings that a vaccine can
be produced against this infection. The O. volvulus vaccine would be indicated as a product
to protect vulnerable populations living in endemic areas against infection and disease.
Reduction in adult worm burden would potentially reduce the number of microfilariae
produced by the adult female worms and thus pathology and potentially also the rates of
transmission within these endemic regions.
A mouse model was developed for studying immunity to the larval stages of O. volvulus in
which larvae are implanted in mice within diffusion chambers (Lange et al., 1993).
Protective immunity was demonstrated in this model following immunization with irradiated
Int J Parasitol. Author manuscript; available in PMC 2015 August 01.
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infective L3s (Lange et al., 1993; Abraham et al., 2001, 2004). To develop a vaccine with
potential clinical application, the model was selected as a moderate throughput means to test
recombinant protein or larval vaccines. Recombinant O. volvulus antigens, selected using a
variety of criteria, were shown previously to exhibit varying degrees of promise as possible
vaccine candidates. In a previously published study, 15 recombinant O. volvulus antigens
out of the 44 screened using the O. volvulus-mouse model were found to be protective
(Lustigman et al., 2002). Based on the following selection criteria, seven of these protective
antigens were selected for further evaluation in the current study: (i) being nematode- or
parasite-specific with or without known function. High sequence homology between parasite
and mammalian proteins has the potential risk of inducing autoimmunity; (ii) localization of
the corresponding native proteins in larvae by immunoelectron microscopy in one or more
regions that are also recognized by antibodies from humans and/or mice with protective
immunity to O. volvulus (Lustigman et al., 2003); (iii) being recognized by antibodies from
humans with protective immunity or cattle, chimpanzees, mice immunized with irradiated
larvae; (iv) the ability of antibodies targeting the parasite antigen to kill larvae in vitro; (v)
having homologues that have been shown to also induce protection in other filarial or
nematode host–parasite systems (Table 1). In addition, CPI-2 was altered by site-directed
mutagenesis to disrupt the asparaginyl endopeptidase inhibitory activity to produced OvCPI-2M (Gregory and Maizels, 2008). It has been demonstrated in the Litomosoides
sigmodontis/mouse system that this alteration of the antigen enhanced the antigen-specific
immune response (Babayan et al., 2012).
The objective of the present study was to produce all candidate vaccine antigens under
controlled conditions, using two protein expression systems, Escherichia coli and the yeast
Pichia pastoris, and to evaluate their vaccine efficacy using a single harmonized
immunization protocol. In addition, we tested the hypothesis that adding protective vaccine
candidates together into a multivalent vaccine would improve the ability of the vaccine to
induce protective immunity.

2. Materials and methods
2.1. Expression and purification of O. volvulus vaccine antigens
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Yeast codon optimized DNAs encoding for selected O. volvulus vaccine candidates: OvB20-C (77 amino acids in the C-terminal region of B20 that were shown to be protective),
Ov-RBP-1, Ov-CPI-2, Ov-CPI-2M, Ov-103, Ov-ALT-1, Ov-RAL-2 and Ov-ASP-1, minus
the signal peptides at the N-terminus, were synthesized by GenScript (Piscataway, NJ, USA)
and subsequently subcloned in-frame into the yeast expression vector pPinkα-HC (Life
Technologies, Carlsbad, CA, USA) with XhoI/KpnI sites and E. coli expression vector
pET41a (EMDMillipore, Billercia, MA, USA) with the fusion GST deleted (NdeI/XhoI).
The correct open reading frame (ORF) was confirmed by double-stranded sequencing using
the vector flanking primers (5′AOX1/CYC1 for pPinkα-HC and T7 promoter/T7 terminator
for pET41a). For expression in yeast, the recombinant plasmids were linearized with AflII
digestion and then transformed by electroporation into PichiaPink strain#4 with protease A
and B knockout (pep4/prb1−) to prevent P. pastoris -derived protease degradation. Yeast
transformants were selected on P. pastoris adenine dropout (PAD) selection plates. The
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expression of recombinant filarial antigens with hexahistidine (6His)-tag at the C-terminus
was induced with 0.5% methanol and the soluble recombinant proteins secreted into the
culture were purified with immobilized metal ion affinity chromatography (IMAC) as
described previously (Goud et al., 2004). For expression in E. coli, the recombinant
constructs cloned into pET41a were transformed into BL21(DE3) (EMDMillipore) and
recombinant proteins were induced with 1 mM isopropyl-β-thiogalactoside (IPTG) and
purified with IMAC as previously described (Zhan et al., 2002).
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In order to test the synergistic protection of two or three O. volvulus protective antigen
combinations, the selected three protective O. volvulus antigens, Ov-103, Ov-RAL-2 and
Ov-CPI-2M, were fused together as a triple antigen (Ov-103-RAL-2-CPI2-M) or as two
double antigens (Ov-103-RAL-2 and Ov-RAL-2-CPI2-M) by using a flexible linker
(KGPDVPETNQQCPSNTGMTD) obtained from Na-ASP-1 structure between two
pathogenesis-related (RP) domains (Asojo et al., 2005). The yeast codon optimized fusion
DNAs were subcloned into either yeast expression vector pPICZαA (Life Technologies) or
E. coli expression vector pET41a (EMD Millipore) with GST knockout. The recombinant
fusion proteins were expressed and purified using the same methods described above except
for the use of yeast strain P. pastoris X-33 (Zhan et al., 2002). The purity and the molecular
weight of purified recombinant proteins were analyzed by SDS-PAGE using pre-cast 4–20%
Tris-glycine gels (Life Technologies) and stained with Coomassie brilliant blue R-250
(Fisher Scientific, Pittsburg, PA USA).
2.2. Source of parasites and mice
Black flies (Simulium damnosum) were fed on consenting donors that were infected with O.
volvulus Institutional Review Board (IRB) protocol 320 approved by the New York Blood
Center, USA and the Kumba, Cameroon IRB). After 7 days the flies were dissected to
collect developed L3s, cleaned and cryopreserved in dimethyl sulfoxide and sucrose by
using Biocool II computerized freezing equipment (FTS Systems Inc., Stone Ridge, NY,
USA) as previously described (Trpis et al., 1993)
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Male BALB/cByJ mice were purchased from The Jackson Laboratory (Bar Harbor Maine,
USA) at 6-8 weeks of age. Mice were kept in the Laboratory Animal Sciences Facility at
Thomas Jefferson University, USA. All mice were housed in micro-isolator boxes in a room
that was pathogen-free and under temperature, humidity and light cycle controlled
conditions. Mice were fed autoclavable rodent chow and given water ad libitum. All
protocols using mice were approved by the Institutional Animal Care and Use Committee of
Thomas Jefferson University.
2.3. Immunization and challenge protocol
Mice were immunized with 25 μg of the produced vaccine antigens in 0.1 ml of Tris
Buffered Saline (TBS) formulated with 0.1 ml of 1:5 Rehydragel LV (alum) in PBS
(General Chemical, Parsippany, NJ, USA). Mice were immunized s.c. in the nape of the
neck, followed by two booster injections 14 and 28 days later.
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Cryopreserved L3s were defrosted slowly in two steps, first 15 min on dry ice followed by a
37 °C water bath. Once thawed, the L3s were washed five times in a 1:1 mixture of NCTCand Iscove's modified Dulbecco's medium with 100 U of penicillin, 100 μg of streptomycin,
100 μg of gentamicin and 30 μg of chloramphenicol per ml. Diffusion chambers were
constructed from 14 mm Lucite rings covered with 5.0 μM pore-size Durapore membranes
(EMDMillipore) and fused together using an adhesive containing a 1:1 mixture of 1,2dichloroethane (Fisher Scientific) and acryloid resin (Rohm and Haas, Philadelphia, PA,
USA). The constructed diffusion chambers were then sterilized via 100% ethylene oxide
followed by 12 h aeration.
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Challenge infections occurred 14 days after the final booster with 25 L3s delivered within a
diffusion chamber. The diffusion chambers were implanted in a s.c. pocket on a rear flank of
each mouse. Recovery of the chambers was performed 21 days later and larval survival was
determined based on mobility and morphology of the remaining larvae. Protective immunity
was calculated in two ways: (i) Percentage of reduction in larvae was calculated as follows:
% reduction = ((average worm survival in control mice - average worm survival in
immunized mice) ÷ average worm survival in control mice) × 100. (ii) Host protection was
calculated as follows: (number of immunized mice with parasite recovery levels below the
lower S.D. of parasite recovery in control mice ÷ total number of immunized mice) × 100.
Host cells within the diffusion chamber were collected and analyzed by centrifugation onto
slides using a Cytospin 3 (Shandon Inc, Pittsburgh, PA, USA) and then stained for
differential cell counts using Hemastain 3 (Fisher Scientific).
2.3. ELISA
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Serum was collected at the time of recovery for antigen-specific IgG analysis. Maxisorp 96well plates (Nunc Nalgene International, Rochester, NY, USA) were coated with 2 ug/ml of
the immunizing recombinant antigen in 50 mM Tris-Cl coating buffer, pH 8.8, overnight at
4°C. Plates were washed with deionized water between each step. Plates were blocked with
borate buffer solution (BBS) (0.17 M boric acid, 0.12 M NaCl, 0.5% tween 20, 0.025%
BSA, 1 mM EDTA, pH 8.2) at room temperature for 30 min. Individual sera were diluted to
an appropriate starting concentration with BBS and serially diluted; plates were sealed and
incubated at 4°C overnight. Biotinylated IgG (eBioscience, San Diego, CA, USA) was
diluted 1:250 in BBS and incubated for 1 h at room temperature, followed by ExtrAvidin Px
(Sigma, St. Louis, MO, USA) which was diluted 1:1000 in BBS and incubated for 30 min at
room temperature. One component ABTS peroxidase substrate (KPL, Gaithersburg, MD,
USA) was added and O.D.s were read after 30 min at 405 nm in a Bio-Rad iMark
Microplate reader (Bio-Rad, Hercules, CA, USA). ELISA data are presented as endpoint
titers which were calculated as the serum dilution from experimental animals that had an
O.D. reading three times higher than the O.D. recorded for control serum.
2.4. Statistical analysis
All experiments consisted of five to six mice per group and experiments were performed at
least twice with consistent results between experiments. Data were analyzed by
multifactorial analysis of variance ANOVA with post-hoc Fisher's Least Significant

Int J Parasitol. Author manuscript; available in PMC 2015 August 01.

Hess et al.

Page 6

Difference (LSD) testing in Systat v.11 (Systat Inc., Evanstown, IL, USA). P < 0.5 was
considered statistically significant.
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3. Results
3.1. Evaluation of antigens expressed in E. coli or P. pastoris for their ability to induce
protective immunity
Efforts were made to express the seven selected O. volvulus antigens and Ov-CPI-2M by
both E. coli and P. pastoris. With the exception of OvB20-C, which could only be expressed
by E. coli, all of the antigens were expressed by both E. coli and P. pastoris. Of the seven
antigens tested, only Ov-103, Ov-RAL-2 and Ov-CPI-2M induced statistically significant
levels of protective immunity in repeated experiments.
3.2. Expression of Ov-103, Ov-RAL-2 and Ov-CPI-2M or fusion recombinant proteins in E.
coli and P. pastoris
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Onchocerca volvulus vaccine candidates were expressed as soluble recombinant proteins in
high yield in P. pastoris and E. coli BL21(DE3) after being induced with 0.5% methanol for
P. pastoris and 1 mM IPTG for E. coli, and purified with IMAC. Purified recombinant
Ov-103, Ov-RAL-2 and Ov-CPI-2M expressed in P. pastoris or in E. coli migrated at the
same molecular mass as calculated by the coding sequence (14.5 kDa, 17.9 kDa and 16.0
kDa, respectively) on SDS-PAGE and Coomassie staining (Fig. 1).
The fusion recombinant proteins of two or three antigen combination (Ov-103-RAL2, OvRAL2-CPI2M and Ov-103-RAL2-CPI2M) were also expressed in P. pastoris and E. coli
expression systems as soluble proteins and the purified recombinant fusions were shown at
the correct molecular weight as estimated by sequences on SDS-PAGE (50.6 kDa, 32.5 kDa
and 35.2 kDa, respectively) (Fig. 2). Some product-derived degradation was observed in the
fusion proteins and these degraded bands could be recognized by anti-His antibody (data not
shown). All recombinant proteins including fusions were able to bind completely to alum
when the ratio of protein and alum was 1:12.8.
3.3. Immunization with single antigens to induce protective immunity against O. volvulus
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3.3.1. Ov-103—BALB/cByJ mice were immunized with Ov-103 with alum prepared in
both P. pastoris and E. coli expression systems. Escherichia coli expressed protein induced
an 8% reduction in larval survival and a 50% level of host protection, whereas mice
immunized with the P. pastoris expressed protein had a statistically significant 30%
reduction in parasite survival and a 63% level of host protection (Fig. 3A). Differential cell
counts were performed at the conclusion of the experiments on the diffusion chamber
contents. Comparable numbers of total cells (1.4×106 ± 1.3×106), and percentages of
lymphocytes (5 ± 7%), neutrophils (52 ± 20%), macrophages (37 ± 15%) and eosinophils
(12 ± 14%) were seen in the control and immunized mice. Parasite-specific antibody titers
show equivalent endpoint titers for mice immunized with P. pastoris and E. coli expressed
Ov-103 when measured against both the P. pastoris and E. coli expressed proteins (Table 2).
Correlation analyses were performed between parasite survival and antibody endpoints titers
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and there were no significant relationships between the amount of antibody produced and
the survival of the larvae.
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3.3.2. Ov-RAL-2—Mice immunized with E. coli expressed Ov-RAL-2 induced a
statistically significant 39% reduction in larval survival and a 64% level of host protection,
whereas mice immunized with the P. pastoris expressed protein induced a 24% reduction in
parasite survival and a 55% level of host protection (Fig. 3B). As with Ov-103, differential
cell counts showed comparable numbers of total cells, lymphocytes, neutrophils,
macrophages and eosinophils in the control and immunized mice. Parasite-specific antibody
titers show equivalent endpoint titers for both the P. pastoris and E. coli expressed proteins
(Table 2). Again, correlations between parasite survival and antibody endpoints titers did not
reveal any significant relationship between the amount of antibody produced and parasite
survival.
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3.3.3. Ov-CPI-2M—Immunization of mice with Ov-CPI-2M expressed in both E. coli and
P. pastoris induced statistically significant reductions of 30% in larval survival and 17%
levels of host protection (Fig. 3C). As with the other two antigens, differential cell counts
showed comparable numbers of total and specific cells in the control and immunized mice,
and parasite-specific antibody titers had equivalent endpoints (Table 2). There were no
significant correlations between antibody endpoint titers and parasite survival.
3.4. Fusion proteins or concurrent immunization with Ov-103, Ov-RAL-2 and Ov-CPI-2M
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Mice were immunized with Ov-RAL-2/103 fusion protein expressed in P. pastoris and E.
coli. Immunization with E. coli expressed protein significantly reduced larval survival by
21% and provided a 58% level of host protection, whereas immunization with P. pastoris
expressed protein only reduced larval survival by 11% and provided a 45% level of host
protection (Fig. 4A). Immunization with Ov-RAL-2/CPI-2M E. coli fusion protein induced
protective immunity with parasite reduction at 34% and a 50% level of host protection (Fig.
4B). Analysis of the cells within the diffusion chamber contents showed similar numbers of
total cells, lymphocytes, neutrophils, macrophages and eosinophils. Parasite-specific
antibody titer endpoints were measured against the individual antigens and the fusion
protein. Antibody endpoint titers for the two fusion proteins were significantly higher than
the antibody responses in these mice to the individual antigens of which the fusion was
composed. The antibody response to Ov-RAL-2 and Ov-CPI-2M by mice immunized with
these antigens as part of a fusion were equivalent to the responses seen in mice immunized
with antigen individually. However, the parasite-specific antibody titer endpoint to Ov-103
was approximately eight-fold higher in mice immunized with the antigen as part of a fusion
compared with immunization with the individual antigen (Table 2). Once again, there were
no significant correlations between antibody endpoints and parasite survival.
A fusion protein consisting of Ov-103, Ov-RAL-2 and Ov-CPI-2M was created to determine
whether enhanced protective immunity would be achieved with this triple fused antigen. The
Ov-RAL-2/103/CPI-2M E. coli fusion was tested in comparison with concurrent
immunization consisting of the three antigens injected simultaneously but at different
locations on the mice. Immunization with the three-antigen fusion protein and the concurrent
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immunization resulted in significant levels of protective immunity, with the fusion inducing
a 20% reduction in larval survival and a 45% level of host protection and the concurrent
immunization resulting in a 25% reduction in parasite survival and a 64% level of host
protection (Fig. 5). Analysis of the cells within the diffusion chamber contents showed
similar numbers of total cells, lymphocytes neutrophils, macrophages and eosinophils.
Antibody titer endpoints were measured against the individual antigens and the fusion
protein. Mice immunized with the three antigens concurrently had antibody endpoint titers
to the three antigens that were comparable with those seen in mice immunized with the three
individual antigens (Table 2). Mice immunized with the three-antigen fusion protein had
endpoint titers to the single antigens that were comparable with the titers seen in mice
immunized with individual antigens. Antibody endpoint titers for the three-antigen fusion
protein were significantly higher than the antibody responses in these mice to the individual
antigens of which the fusion was composed (Table 2). There were no significant correlations
between antibody endpoints and parasite survival.

4. Discussion
NIH-PA Author Manuscript

Previous studies have identified several antigens with either proven or potential efficacy in a
vaccine against infection with O. volvulus. One of the challenges in comparing these studies
is the range of approaches used to produce the recombinant antigens, which were performed
by laboratories across the USA and Europe, and the immunization protocols used to test
these antigens (Lustigman et al., 2002). The objective of the present study was to produce
the eight tested vaccine antigens under controlled conditions, using two expression systems
and in one laboratory, and to evaluate their vaccine efficacy using a single immunization
protocol. In addition, we tested the hypothesis that joining protective antigens as a fusion
protein or in combination into a multivalent vaccine would improve the ability of the
vaccine to induce protective immunity.
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Out of the eight antigens tested, only Ov-103, Ov-RAL-2 and Ov-CPI-2M were able to
repeatedly induce protective immunity under the experimental conditions used in the present
study. There are numerous possible explanations for why the other vaccine antigens did not
induce protective immunity as was previously reported, including the immunization
regimen, adjuvant formulation, expression system and type of challenge infection. All of the
tested antigens evoked significant antibody responses, which suggests that the immunization
regimen was adequate. There may have been inadequate activation of other elements of the
immune response that collaborate with antibody to kill the parasites.
Previous studies on the role of adjuvants in development of recombinant-antigen vaccines
against O. volvulus have demonstrated that either alum (Abraham et al., 2001) or FCA was
required (McCarthy et al., 2002) or that either adjuvant was successful at enhancing the
capability of the antigen to induce protective immunity to the parasite (MacDonald et al.,
2004). Immunity to O. volvulus induced by irradiated larvae is dependent on Th2 responses
(Lange et al., 1994; Abraham et al., 2004) and alum has the recognized ability to stimulate
humoral immunity and strong Th2 responses (Kenney et al., 1989; Brewer et al., 1996; Yip
et al., 1999). In addition, alum remains one of the few adjuvants that is commonly used in
human vaccines, whereas FCA is not recommended for use in humans. Alum was therefore
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selected for use in this study due to its predilection for inducing Th2 responses and due to its
acknowledged safety in humans.
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Two different expression systems were used in this study. Escherichia coli was selected as it
was the original system in which the antigens were produced. Pichia pastoris was used as it
provides an expression system in which there are post-translational modifications such as
glycosylation that will potentially yield antigens more closely resembling the native proteins
(Hohenblum et al., 2004). Seven of the eight tested O. volvulus antigens were successfully
produced in both expression systems with Ov-B20-C only produced in E. coli. The finding
that some antigens are preferentially expressed in one system over the other has been
observed with other antigens (Zhang et al., 2006). Interestingly, all eight antigens, regardless
of the expression system, induced robust antibody responses. The three antigens that
induced protective immunity had equivalent antibody endpoint titers regardless of the
expression system and there was comparable recognition of the antigens from the two
expression systems regardless of the source of the immunizing antigen. Yet, mice
immunized with P. pastoris expressed Ov-103 had a statistically significant reduction in
parasite survival but not with E. coli expressed antigen; Ov-RAL-2 induced a statistically
significant reduction in parasite survival only if produced by E. coli; and Ov-CPI-2M
produced in either Pichia or E. coli induced protective immunity. In other studies, no
differences were observed in the immune responses induced by E. coli and Pichia expressed
antigens (Giersing et al., 2005), whereas some antigens were more immunogenic if produced
in E. coli compared with Pichia (Kastenmuller et al., 2013) and yet other antigens were
more antigenic if produced in Pichia compared with E. coli (Yang et al., 2012).
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Two metrics were used to measure the development of protective immunity. “Larval
survival” assessed the number of larvae that were killed in immunized compared with
control mice and describes the level of protective immunity within individual mice. “Host
protection” measured the percentage of mice that developed significant resistance to the
infection and reflects the level of protective immunity within the host population.
Immunization with the three protective antigens resulted in equivalent levels of protective
immunity based on both metrics. Efforts to resolve why an antigen expressed in one system
induced protective immunity, whereas expression in the other system did not induce
protective immunity, were not informative. There were no correlations between antigenspecific antibody levels and the number of larvae killed in a mouse. The number and types
of cells that migrated into the parasite microenvironment did not vary between control and
immunized animals nor between immunized mice that developed protective immunity and
immunized mice that did not develop protective immunity. Further analysis of the immune
response is required to resolve the molecular mechanism of parasite killing induced by the
recombinant antigens. Antibody class and subclass responses, as well as the binding affinity
of the antigen-specific antibodies, may govern the potency of the antibodies. Cell analysis
needs to be expanded to observe the cells in the parasite microenvironment at the time prior
to parasite killing and at the time of larval death. Furthermore, it has been shown that the
effector cell eosinophils (Lee et al., 2010), macrophages (Bonne-Annee et al., 2013) and
neutrophils (Tsuda et al., 2004; Christoffersson et al., 2012) undergo specific forms of
activation dependent on the host or pathogen factors to which those are exposed. It is
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possible that effector cells are recruited to the parasite microenvironment, but are ineffectual
due to their activation status. It is hypothesized that in mice with protective immunity, cells
are recruited to the parasite and specifically activated into a state in which they can
participate with antibody in the killing process.
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Multivalent vaccines have been successfully developed against the filarial worm Brugia
malayi (Anand et al., 2011; Joseph and Ramaswamy, 2013; Shrivastava et al., 2013) and
immunization of calves with a multivalent vaccine against Onchocerca ochengi reduced the
development of patency as determined by a decrease in the number of animals with
microfilariae in the skin (Makepeace et al., 2009). It was hypothesized that immunizing
mice against O. volvulus with two or three of the protective antigens would induce elevated
levels of protective immunity. Concurrent immunization of mice with all three protective
antigens did not induce increased levels of protective immunity compared with
immunization with the individual antigens. In a previous study utilizing three recombinant
O. volvulus antigens, immunization with the three antigens as a cocktail also resulted in
levels of protective immunity equivalent to that induced by the component individual
antigens (Abraham et al., 2001). Analysis of antibody responses following immunization
with the cocktail of three antigens revealed that some of the antibody responses were
reduced compared with that seen in mice immunized with individual antigens (Abraham et
al., 2001). It was hypothesized that there was competition between the antigens in the
cocktail, with some of the antigens dominating the immune response (Abraham et al., 2001).
Therefore, in the current study the three antigens were injected concurrently and in different
locations on the mice. The result was antibody responses to the three antigens that were not
diminished, yet did not result in elevated levels of protective immunity.
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As an alternative approach, fusion proteins consisting of two or three of the protective
recombinant antigens were tested for their efficacy in the vaccine against infection with O.
volvulus. Mice immunized with Ov-RAL-2/103, Ov-RAL-2/CPI-2M or Ov-103/RAL-2/
CPI-2M fusion proteins had significant levels of larval killing and host protection. Mice
immunized with the two or three-antigen fusion proteins had endpoint titers to the single
antigens that were at least comparable with the titers seen in mice immunized with
individual antigens. Antibody endpoint titers for the fusion proteins were significantly
higher than the antibody responses in these mice to the individual antigens of which the
fusions were composed. Even in the face of the significantly enhanced antibody titers the
levels of protective immunity were not enhanced in the mice immunized with the double or
triple fusion proteins. Fusion protein vaccines developed against Plasmodium falciparum
have better efficacy than antigen cocktails (Faber et al., 2007, 2013; Alaro et al., 2013). A
multivalent fusion protein vaccine against B. malayi conferred 95% protection in mice
(Dakshinamoorthy et al., 2013). Interestingly, it was concluded in a recent review that mice
have a high degree of natural resistance to infection with B. malayi and that almost every
reported vaccine trial using a wide range of vaccine components has demonstrated efficacy
in mice against infection with B. malayi (Morris et al., 2013). Mice are resistant to infection
with both B. malayi and O. volvulus, yet high levels of protective immunity can be induced
against B. malayi, whereas only moderate levels of immunity can be induced against O.
volvulus in mice regardless of the immunization regimen. A possible explanation is that O.
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volvulus may have developed immune evasion mechanisms, differing from those developed
by B. malayi, that the mouse immune response cannot supersede.
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In summary, out of eight vaccine candidates tested in this study, Ov-103, Ov-RAL-2 and OvCPI-2M - individually, as fusion proteins and in combination - were shown to reproducibly
induce protective immunity in mice. The levels of protective immunity that were induced by
these antigens were moderate and may reflect a limitation of the ability of the immune
response ability to kill parasites within diffusion chambers. Jirds immunized against
Acanthocheilonema viteae displayed low levels of parasite killing within diffusion chambers
while simultaneously killing parasites within the tissues (Taylor et al., 1995). Alternatively,
the limited time of exposure that the immune response had to the parasites may have
retarded the ability of the immune response to kill the worms. Evidence from immunization
trials against Dirofilaria immitis in dogs have shown that the protective immune response
killed approximately 50% of the parasites contained within diffusion chambers at 3 weeks
post-challenge and 98% of the parasites at 6 months post-challenge (Grieve et al., 1988). In
parallel experiments to those described in this study, Mongolian gerbils were vaccinated
with homologous B. malayi antigens produced in the same protein expression systems and
administered using the same adjuvants and vaccine schedules described herein. Significant
reductions in adult worm recovery were seen in gerbils vaccinated with Bm-103, Bm-RAL-2
and Bm-CPI-2M (T. Klei, unpublished data). We therefore posit that the levels of protective
immunity observed in the current study, induced by the three protective antigens, do not
reflect the true potential of these vaccines to induce protective immunity in the clinical
setting. Although the present data do not take into account repeated exposures which occur
in the field during ongoing transmission, we still submit that a vaccine composed of these
three antigens will function in humans at levels greatly exceeding those seen in mice and
will protect the vaccinated individuals from infection and disease caused by O. volvulus.
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A vaccine against onchocerciasis is essential for the control of this disease
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Three antigens were shown to induce protective immunity against Onchocerca
volvulus
Multivalent vaccine did not increase protective immunity
Antigens remain candidates for inclusion in onchocerciasis vaccine for humans
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Fig. 1.

SDS-PAGE and Coomassie staining of purified recombinant Onchocerca volvulus Ov-103,
Ov-RAL-2 and Ov-CPI-2M proteins expressed in Pichia pastoris (yeast) and Escherichia
coli. SeeBlue pre-stained proteins (Invitrogen) were used as standard markers. A total of 1
μg was loaded for each recombinant protein.
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Fig. 2.
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SDS-PAGE of purified recombinant fusion proteins and their construct diagrams (A – C).
The fusion proteins of three or two protective Onchocerca volvulus (Ov) filarial antigen
combinations were constructed as shown in the diagram. The recombinant fusion proteins
were expressed in Pichia pastoris (yeast) and Escherichia coli and loaded on SDS-PAGE
(each 1 μg, indicated with arrows). SeeBlue pre-stained proteins (Invitrogen) were used as
standard markers. 6His, 6-hexahisitidine tag.
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Fig. 3.

Effect of immunization with a single vaccine antigen expressed by either Escherichia coli or
Pichia pastoris on the development of protective immunity to Onchocerca volvulus larvae in
mice. (A) Ov-103; (B) Ov-RAL-2; (C) Ov-CPI-2M. Each dot represents larval recovery
from an individual animal. Data presented are mean ± S.D. Asterisk represents statistical
difference in larval recoveries; P ≤ 0.05.
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Fig. 4.

Effect of immunization with fusion antigens on the development of protective immunity to
Onchocerca volvulus larvae in mice. (A) Ov-RAL-2/103 fusion protein expressed in
Escherichia coli and Pichia pastoris expressed protein. (B) Ov-RAL-2/CPI-2M expressed in
E. coli. Each dot represents larval recovery from an individual animal. Data presented are
mean ± S.D. Asterisk represents statistical difference in larval recoveries; P ≤ 0.05.
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Fig. 5.

Comparative effect of immunization with concurrent injections of Onchocerca volvulus
Ov-103 (expressed in Pichia pastoris), Ov-RAL-2 (expressed in Escherichia coli) and OvCPI-2M (expressed in E. coli) compared with immunization with the combined fusion
antigen Ov-RAL-2/103/CPI-2M (expressed in E. coli). Each dot represents larval recovery
from an individual animal. Data presented are mean ± S.D. Asterisk represents statistical
difference in larval recoveries; P ≤ 0.05.
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Bm-ALT-2 (Bm)

-Bm-ALT-1 (Bm) (Gregory et al.,
2000)

-Ac-ASP-2 (Ac) (Goud et al.,
2004)

-Bm-ASP-1(Bm) (Anand et al.,
2011)

-rAc-16 (Ac) (P. Hotez,
unpublished data)

-rAs16 (As) (Tsuji et al., 2004;
Tsuji et al., 2003; Tsuji et al.,
2001)

-rWb-SXP/Bm14 (Bm)(Wang et
al., 1997)

-Ac-SAA-1 (Ac) (Zhan et al., 2004)

-Ls-cystatin (mutated) (Ls)
(Babayan et al., 2012)

-Ac-cystatin (Ac) (P. Hotez,
unpublished data)

-Ls-cystatin (Ls) (Pfaff et al.,
2002)

Protection in other filaria or
nematode animal models

Characteristic of nematode
orthologous proteins

Ac, Ancylostoma ceylanicum; As, Ascaris suum; Av, Acanthocheilonema viteae; Bm, Brugia malayi; ES, excretory-secretory product; Ls, Litomosoides sigmodontis ; Mf, microfilaria; ND, Not
determined; Ov, Onchocerca volvulus; Ol, O Onchocerca lienalis; Wb, Wuchereria bancrofti.

Onchocystatin, (Cysteine
protease inhibitor)

Identity (Function)

Ov-CPI-2 M37105 (17)

Antigen accession # (kDa)

Characteristics of the O. volvulus protective protein

Characteristics of seven antigens selected for further development into a vaccine against infection with Onchocerca volvulus.
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NIH-PA Author Manuscript
317,320

16,019

Ov-RAL-2, 103, CPI-2M Concurrent

Ov, Onchocerva volvulus

146,607

90,464

Ov-RAL-2/103/CPI-2M Fusion
271,416

187,884

Ov-RAL-2/CPI-2M Fusion

439,250

392,676

165,510

266,079

462,057

Ov-103/RAL-2 Fusion

431,803

Ov-CPI-2M P. pastoris

CPI-2M

Ov-CPI-2M E. coli

571,055
519,490

Ov-RAL-2 E. coli

35,882

RAL-2

Ov-RAL-2 P. pastoris

33,064

Ov-103 Pichia pastoris

103

Ov-103 Escherichia coli

Immunizing Antigen

1,509,278

RAL-2/103

691,063

RAL-2/CPI-2M

Endpoint Titer to Antigen

1,112,542

RAL-2/103/CPI-2M

Geometric mean of IgG endpoint titers following immunization with individual, fusion or concurrent antigen formulations. Ov- Onchocerva
volvulus
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